Australian drug regulators have approved a new aqueous, immunosuppressant for the treatment of moderate-to-severe dry eye.
Read More
Novartis secures approval for AMD drug in Australia
Australia’s ophthalmic community has welcomed the approval of Novartis’ latest therapy for neovascular age-related macular degeneration (nAMD). Advocates hope the decision will lift treatment adherence rates across the country.
Read More
Read More